Brief Report: Aumolertinib as a Switch Therapy in Osimertinib-Intolerant NSCLC-The ACTIVE Trial.
Free. We’ll email you when a new paper cites this one or any other paper you follow on JClub — at most one email a day. Every email has a one-tap unsubscribe.